Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

Calendar

08-06 Earnings release - Q2 2026

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.890EUR

Average target price

9.720EUR

Spread / Average Target

+414.29%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP

Market Cap	46.84M 53.94M 43.67M 40.12M 75.88M 5.13B 76.71M 515M 201M 2.57B 203M 198M 8.5B	P/E 2026 *	-3.05x	P/E 2027 *	-2.86x
Enterprise Value	39.54M 45.54M 36.87M 33.87M 64.05M 4.33B 64.75M 435M 170M 2.17B 171M 167M 7.17B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	38.21%	Yield 2026 *	-	Yield 2027 *	-

07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-22	Eckert & Ziegler next in BaFin's sights, shares rebound	DP
07-22	Eckert & Ziegler Faces BaFin Review Over Pentixapharm Spin-off Accounting	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-09	Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism	CI
07-09	Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA	MT
06-09	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
06-09	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI
06-09	Pentixapharm Gains US FDA Clearance for Late-stage PentixaFor Study	MT
06-09	Pentixapharm to Raise EUR20 Million via Capital Increase	MT
06-09	Pentixapharm Holding AG Announces Positive Feedback From FDA For Initiation Of Phase III PANDA Study With [68Ga]Ga-PentixaFor	CI
05-11	Pentixapharm Holding AG Announces IND Submission To FDA For Phase 3 PANDA Study Of CXCR4-Targeted Cardiovascular Diagnostic	CI

07-27	Pentixapharm Completes Capital Increase – New Shares Placed in Full	EQ
07-27	Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today	EQ
07-23	Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement	AQ
07-22	Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement	EQ
07-09	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Granting of 8.922.464 Subscription rights	EQ

Pentixapharm Holding AG Stock OTC Markets

Stocks

PTPDF

DE000A40AEG0

Pharmaceuticals

Valuation: Pentixapharm Holding AG

Latest news : Pentixapharm Holding AG

Press Releases: Pentixapharm Holding AG

News in other languages: Pentixapharm Holding AG

Course Extremes

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

08-04	Pentixapharm Holding AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07-27	Pentixapharm Holding AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG
07-27	Pentixapharm : schließt Kapitalerhöhung ab und erzielt Bruttoerlöse von insgesamt rund EUR 20,4 Millionen aus der vollständigen Platzierung neuer Aktien, um die PANDA-Phase-3-Studie voranzutreiben.
07-27	Pentixapharm schließt Kapitalerhöhung ab – Neue Aktien vollständig platziert
07-27	Pentixapharm Holding AG schließt Bezugsangebot mit Privatplatzierung bereits heute mit deutlicher Überzeichnung ab und erzielt einen Bruttoerlös von rund EUR 20,4 Millionen

Current year	0		2.31
1 year	0		2.31
3 years	0		2.31
5 years	0		2.31
10 years	0		2.31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	-.--%	-.--%	-	-	54.32M
ELI LILLY AND COMPANY	-0.51%	-6.83%	+46.35%	+148.39%	1T
JOHNSON & JOHNSON	+0.20%	-4.14%	+52.35%	+49.40%	613B
ABBVIE INC.	-0.53%	-5.10%	+24.88%	+63.57%	433B
ROCHE HOLDING AG	+0.48%	-0.67%	+39.13%	+34.00%	350B
NOVARTIS AG	+0.08%	-3.05%	+32.29%	+39.91%	292B
ASTRAZENECA PLC	+2.09%	-8.91%	+5.73%	+7.71%	239B
NOVO NORDISK A/S	+1.75%	-5.79%	-0.39%	-42.69%	206B
AMGEN INC.	+2.94%	+3.66%	+31.37%	+69.06%	204B
GILEAD SCIENCES, INC.	+3.13%	+3.62%	+19.50%	+79.07%	163B
Average	+1.06%	-3.88%	+27.91%	+49.82%	388.94B
Weighted average by Cap.	+0.72%	-4.34%	+35.20%	+71.36%

	2026 *	2027 *
Net sales	-	-
Net income	-22.3M -25.68M -20.79M -19.1M -36.12M -2.44B -36.52M -245M -95.83M -1.22B -96.44M -94.33M -4.05B	-23.5M -27.06M -21.91M -20.13M -38.07M -2.57B -38.49M -258M -101M -1.29B -102M -99.41M -4.26B
Net Debt	-7.3M -8.41M -6.81M -6.25M -11.83M -800M -11.96M -80.24M -31.37M -400M -31.57M -30.88M -1.32B	12.3M 14.17M 11.47M 10.54M 19.92M 1.35B 20.14M 135M 52.85M 674M 53.2M 52.03M 2.23B